Literature DB >> 16565869

Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists.

Farida Daïkha-Dahmane1, Evelyne Levy-Beff, Myriam Jugie, Richard Lenclen.   

Abstract

We report renal lesions observed in a foetus exposed throughout pregnancy to angiotensin II type I (AT 1) receptor antagonists. The mother suffered from essential hypertension and was treated with Cozaar (losartan 50 mg). Autopsy examination of the foetus revealed severe renal lesions, including tubular dysgenesis, hypertrophy of the endothelial and medial cells lining the arterial and arteriolar walls, hyperplasia of the juxtaglomerular apparatus and poorly developed vasa recta. Similar lesions have already been observed in foetuses of women treated with angiotensin-converting enzyme antagonists and also in foetuses and neonates of animals undergoing experimental blockade of the renin-angiotensin system. The purpose of this report is to describe structural lesions observed in the kidneys, and, particularly, vascular lesions. Our results suggest that the use of AT 1 receptor antagonists during pregnancy may have a severe deleterious effect on kidney development in the foetus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16565869     DOI: 10.1007/s00467-006-0070-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  24 in total

1.  "Medullary ray glomerular counting" as a method of assessment of human nephrogenesis.

Authors:  S A Hinchliffe; P H Sargent; Y F Chan; D van Velzen; C V Howard; J L Hutton; D I Rushton
Journal:  Pathol Res Pract       Date:  1992-08       Impact factor: 3.250

Review 2.  Branching morphogenesis and kidney disease.

Authors:  Mita M Shah; Rosemary V Sampogna; Hiroyuki Sakurai; Kevin T Bush; Sanjay K Nigam
Journal:  Development       Date:  2004-04       Impact factor: 6.868

Review 3.  Role of angiotensin in renal vascular development.

Authors:  R A Gomez
Journal:  Kidney Int Suppl       Date:  1998-09       Impact factor: 10.545

4.  Histopathological and ultrastructural effects of Losartan on embryonic rat kidney.

Authors:  Ipek Akil; Sevinc Inan; Beyhan Gurcu; Aysegul Nazikoglu; Kemal Ozbilgin; Sevda Muftuoglu
Journal:  Acta Histochem       Date:  2005-09-21       Impact factor: 2.479

Review 5.  Angiotensin II and tubular development.

Authors:  Gunter Wolf
Journal:  Nephrol Dial Transplant       Date:  2002       Impact factor: 5.992

6.  Losartan and fetal toxic effects.

Authors:  H Saji; M Yamanaka; A Hagiwara; R Ijiri
Journal:  Lancet       Date:  2001-02-03       Impact factor: 79.321

7.  Angiotensinogen gene null-mutant mice lack homeostatic regulation of glomerular filtration and tubular reabsorption.

Authors:  S Okubo; F Niimura; T Matsusaka; A Fogo; B L Hogan; I Ichikawa
Journal:  Kidney Int       Date:  1998-03       Impact factor: 10.612

8.  Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats.

Authors:  S G Spence; H L Allen; M A Cukierski; J M Manson; R T Robertson; R S Eydelloth
Journal:  Teratology       Date:  1995-06

9.  Evaluation of the reproductive and developmental toxicity of the AT1-selective angiotensin II receptor antagonist losartan in rats.

Authors:  S G Spence; M A Cukierski; J M Manson; R T Robertson; R S Eydelloth
Journal:  Teratology       Date:  1995-06

10.  Transforming growth factor-beta 1 induces vascular endothelial growth factor expression in murine proximal tubular epithelial cells.

Authors:  Shinji Kitamura; Yohei Maeshima; Takeshi Sugaya; Hitoshi Sugiyama; Yasushi Yamasaki; Hirofumi Makino
Journal:  Nephron Exp Nephrol       Date:  2003
View more
  17 in total

Review 1.  Development of the kidney medulla.

Authors:  Renfang Song; Ihor V Yosypiv
Journal:  Organogenesis       Date:  2012-01-01       Impact factor: 2.500

2.  Dependence of renal microvessel density on angiotensin II: only in the fetus?

Authors:  Barbara J Ballermann
Journal:  J Am Soc Nephrol       Date:  2010-02-18       Impact factor: 10.121

3.  Renovascular hypertension commencing during fetal life.

Authors:  Shivaram Hegde; Christopher Wright; Mohan Shenoy; Nadeem E Moghal; Malcolm G Coulthard
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-09-21       Impact factor: 5.747

4.  Chronic captopril treatment reveals the role of ANG II in cardiovascular function of embryonic American alligators (Alligator mississippiensis).

Authors:  Casey A Mueller; John Eme; Kevin B Tate; Dane A Crossley
Journal:  J Comp Physiol B       Date:  2018-04-06       Impact factor: 2.200

Review 5.  Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension.

Authors:  Florian Herse; Babbette LaMarca
Journal:  Am J Reprod Immunol       Date:  2012-12-28       Impact factor: 3.886

6.  Ovine fetal renal development impacted by multiple fetuses and uterine space restriction.

Authors:  K M Meyer-Gesch; M Y Sun; J M Koch; J Ramadoss; S E Blohowiak; R R Magness; P J Kling
Journal:  J Dev Orig Health Dis       Date:  2013-10       Impact factor: 2.401

Review 7.  Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review.

Authors:  Chisa Shimada; Rina Akaishi; Kazutoshi Cho; Mamoru Morikawa; Yosuke Kaneshi; Takahiro Yamda; Hisanori Minakami
Journal:  Hypertens Res       Date:  2015-02-19       Impact factor: 3.872

8.  Angiotensin II promotes development of the renal microcirculation through AT1 receptors.

Authors:  Kirsten Madsen; Niels Marcussen; Michael Pedersen; Gitte Kjaersgaard; Carie Facemire; Thomas M Coffman; Boye L Jensen
Journal:  J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 10.121

Review 9.  The metabolic syndrome in women.

Authors:  Rhonda Bentley-Lewis; Katherine Koruda; Ellen W Seely
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-10

10.  Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker.

Authors:  Claudio Celentano; Federico Prefumo; Elena di Vera; Annamaria Iannicco; Davide Pio Gallo; Marco Liberati
Journal:  Pediatr Nephrol       Date:  2007-09-26       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.